TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20642550
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg once daily) and Itraconazole (200 mg once daily)
Study: 17451383
Drug: 2% minoxidil
Normalized name: MINOXIDIL 2 g in 100 mL TOPICAL LIQUID [2% Minoxidil hair growth serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% minoxidil solution twice daily for 12 months
Study: 17451383
Drug: 0.025% alfatradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% alfatradiol solution once daily for 6 months, then 2% minoxidil for months 7-12
Study: 7583900
Drug: Intra-articular buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular buprenorphine (0.30 mg)
Study: 8104017
Drug: Ebastine 30
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 30 mg
Study: 26501782
Drug: Time on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time on treatment
Study: 22818804
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instruction (OHI) only
Study: 22818804
Drug: OHI and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OHI and 0.2% chlorhexidine mouth rinse twice daily
Study: 22818804
Drug: OHI, 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: OHI, 0.2% chlorhexidine mouth rinse twice daily, and assisted brushing twice weekly
Study: 20922564
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZA) 4 mg IV, every 6 months
Study: 17530360
Drug: Interferon-alpha2a plus
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha2a plus 15 mg/kg per day of ribavirin (6 MU/day for 4 weeks, then 3 MU/day for 44 weeks)
Study: 17530360
Drug: Interferon-alpha2a plus
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha2a plus ribavirin plus 200 mg/day of amantadine (6 MU/day for 4 weeks, then 3 MU/day for 44 weeks)
Study: 12588054
Drug: Interdisciplinary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdisciplinary therapy (102 subjects)
Study: 8153377
Drug: Conventional fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionated treatment
Study: 8153377
Drug: Both CHART
Normalized name: Stachybotrys chartarum
DrugBank: Stachybotrys chartarum (DB10847)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both CHART and conventional treatment
Study: 2537340
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg clomipramine (CMI)
Study: 2537340
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg clomipramine (CMI)
Study: 27836356
Drug: Senna (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senna (maximum daily dose of 38.7mg)
Study: 14988614
Drug: Intravenous tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tirofiban infusion
Study: 11863317
Drug: Hirudin-containing cream
Normalized name: hirudin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudin-containing cream (Hirudex cream; Hirudo medicinalis extract 280 UI/100 g) applied 3-4 times daily for 5 days
Study: 9689372
Drug: Bupivacaine and
Normalized name: bupivacaine and meloxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine and morphine with epinephrine
Study: 8743003
Drug: 0.5% betaxolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% betaxolol twice daily
Study: 2541335
Drug: Acyclovir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (800 to 3200 mg per day, starting 6 hours before transplantation for 12 weeks)
Study: 12113
Drug: Bromazepam (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam (0.1 mg/kg b.w. i.v.)
Study: 16882344
Drug: Carboplatin AUC
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 5 plus pegylated liposomal doxorubicin 30 mg/m2, every 3 weeks
Study: 14990150
Drug: Hyperoxygen compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperoxygen compound sodium chloride solution (HCSCS)
Study: 14990150
Drug: Control sodium
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control sodium chloride solution (CSCS)
Study: 15001936
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine (group 1)
Study: 15001936
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine (group 2)
Study: 15001936
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (group 3)
Study: 8226141
Drug: Fast neutron
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast neutron radiation therapy (20.4 Gy in 12 fractions)
Study: 3768575
Drug: Placebo (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inhaled aerosol described as a powerful new drug)
Study: 3768575
Drug: Bronchoconstrictive suggestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchoconstrictive suggestion (inhaled nebulized water described as likely to cause chest tightness and wheezing)
Study: 3768575
Drug: Control (distilled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (distilled nebulized water inhaled without suggestion)
Study: 28350929
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 + Calcium (2000 IU/d of vitamin D3 and 1500 mg/d of calcium)
Study: 23303057
Drug: Hydrocortisone (HCT)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HCT) 25 mg/day over 4 days
Study: 23303057
Drug: Hydrocortisone (HCT)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HCT) 100 mg single dose
Study: 9493587
Drug: 90 anti-Xa
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 anti-Xa IU x kg(-1) b.i.d. of the 10,250 IU preparation (treatment A)
Study: 9493587
Drug: 180 anti-Xa
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 anti-Xa IU x kg(-1) o.d. of the 20,500 IU preparation (treatment B)
Study: 4583184
Drug: Ibuprofen 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 1,200 mg daily
Study: 21784296
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy (BT) protocol consisting of eight weekly sessions
Study: 19627350
Drug: Oral health-promotion
Normalized name: Healthy Mama Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health-promotion approach
Study: 16883311
Drug: G‐CSF and
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF and GM‐CSF (5 x 2 microg/kg/day)
Study: 16883311
Drug: G‐CSF and
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF and GM‐CSF (2.5 x 2 microg/kg/day)
Study: 16883311
Drug: G‐CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (5 microg/kg/day)
Study: 16883311
Drug: G‐CSF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF plus GM‐CSF
Study: 9586615
Drug: Levofloxacin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (250 mg once daily for 7 to 10 days)
Study: 9586615
Drug: Lomefloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomefloxacin (400 mg once daily for 14 days)
Study: 26028058
Drug: High-protein (HP)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein (HP) breakfast (350 kcal, 35 g protein)
Study: 19283884
Drug: All-trans retinoyl
Normalized name: all-trans-retinol
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All-trans retinoyl glucuronide (RAG) administered orally to Group II (n 42), blood collected 4 hours after dosing.
Study: 17719942
Drug: Prebiotic supplement
Normalized name: FlorastorSelect Gut Boost Daily Probiotic and Prebiotic Supplement Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic supplement (with calcium intake > or = 700 mg/d)
Study: 15030839
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (lidocaine hydrochloride 2% gel)
Study: 15030839
Drug: Regional anesthesia
Normalized name: ACL6SP45 REGIONAL ANESTHESIA KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional anesthesia (peribulbar or retrobulbar injection of lignocaine 2%)
Study: 9390011
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 0.03 mg/kg
Study: 7886391
Drug: Loperamide (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (16 mg, orally)
Study: 7886391
Drug: Distilled water
Normalized name: Distilled Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distilled water (intraluminal infusion)
Study: 7886391
Drug: Loperamide (intraluminal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (intraluminal infusion)
Study: 3279743
Drug: Isosorbide-5-mononitrate (IS-5-MN)
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (IS-5-MN) 20 mg 3 times a day or 50 mg in a sustained-release tablet
Study: 3279743
Drug: Nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 20 mg in a sustained-release tablet 3 times a day
Study: 20220206
Drug: Choline intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline intake 300 mg/d
Study: 20220206
Drug: Choline intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline intake 550 mg/d
Study: 20220206
Drug: Choline intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline intake 1100 mg/d
Study: 20220206
Drug: Choline intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline intake 2200 mg/d
Study: 20220206
Drug: Choline intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline intake 300 mg/d and 550 mg/d
Study: 10553933
Drug: Yeast-derived vaccine
Normalized name: YEAST CELL,LIVE DERIVATIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast-derived vaccine
Study: 8572340
Drug: Propofol/Alfentanil combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol/Alfentanil combination
Study: 1441044
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg orally twice daily for 10-21 days)
Study: 1441044
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg orally every 12 hours for 14-21 days)
Study: 21143904
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose rate (LDR) Ra‐226 brachytherapy (n = 4; median 70Gy)
Study: 21143904
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose rate (HDR) Ir‐192 brachytherapy (n = 4; 60 Gy)
Study: 16250032
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b plus ribavirin 15 mg/kg/d
Study: 30488303
Drug: Image-guided high-dose-rate
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Image-guided high-dose-rate (HDR) brachytherapy (iBT)
Study: 17978833
Drug: Contrast water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast water therapy (CWT)
Study: 12900682
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO3; 0.3 g.kg−1)
Study: 12900682
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride (NaCl; 0.045 g.kg−1)
Study: 11011709
Drug: Sequential bilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential bilateral PRK
Study: 8450243
Drug: Nucleoside therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleoside therapy (zidovudine, 2',3'-dideoxyinosine, or both) for a mean of 20 months
Study: 8450243
Drug: Nucleoside therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleoside therapy
Study: 24805282
Drug: SONO (ultrasound-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: SONO (ultrasound-guided quadruple injection axillary block)
Study: 24805282
Drug: STIM (nerve
Approvals — FDA: no, EMA: no, PMDA: no
Description: STIM (nerve stimulation-guided triple injection axillary block)
Study: 23186567
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl (sterile saline) solution
Study: 20473257
Drug: Lower-dose corticosteroids
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose corticosteroids
Study: 20473257
Drug: Short-duration, high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-duration, high-dose glucocorticoid therapy
Study: 20473257
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses for persistent ARDS
Study: 17703218
Drug: Prelox (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prelox (combination of L‐arginine aspartate and Pycnogenol)
Study: 12422064
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg opipramol
Study: 21577010
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg opipramol
Study: 10325662
Drug: Active NSAID
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active NSAID (Piroxicam 20 mg)
Study: 10325662
Drug: Active NSAID
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active NSAID (Meloxicam 15 mg)
Study: 10325662
Drug: Active NSAID
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active NSAID (Meloxicam 22.5 mg)
Study: 1770156
Drug: Triazolam 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.50 mg for 1, 6, and 12 nights
Study: 1770156
Drug: Triazolam 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.50 mg for 12 nights
Study: 1770156
Drug: Triazolam 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.50 mg for 1 and 6 nights
Study: 27964756
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) 2 g
Study: 27964756
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of RF, anti-CCP, and high serum IgG
Study: 20025635
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg isoflavones (60 mg of genistein)
Study: 18162021
Drug: Aripiprazole (20-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (20-30 mg/day)
Study: 18162021
Drug: Haloperidol (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (5-10 mg/day)
Study: 11546945
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil 120 mg once daily
Study: 9128034
Drug: Low flow
Normalized name: high mallow flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low flow anesthesia (300 ml.min‐1 of oxygen, 300 ml.min‐1 of nitrous oxide or 400 ml.min‐1 of oxygen, 200 ml.min‐1 of nitrous oxide)
Study: 9128034
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow anesthesia (2 l.min‐1 of oxygen, 4 l.min‐1 of nitrous oxide)
Study: 8179457
Drug: Heparin protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin protocol (5000 U bolus, followed by 1680 U/h or 1240 U/h)
Study: 3067749
Drug: Daily relaxation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily relaxation technique for 3 weeks
Study: 18724648
Drug: Tretinoin microsphere
Normalized name: tretinoin microsphere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin microsphere gel 0.04% applied once nightly for 12 weeks
Study: 23633700
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle gel (placebo)
Study: 18724649
Drug: Tretinoin microsphere
Normalized name: tretinoin microsphere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin microsphere gel 0.04%
Study: 10563706
Drug: Concurrent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent therapy with zidovudine, lamivudine, loviride and zalcitabine (T4)
Study: 10563706
Drug: Cyclical therapy
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical therapy with the same four drugs (C4)
Study: 10563706
Drug: Concurrent zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent zidovudine and lamivudine (T2)
Study: 8688345
Drug: Ondansetron 16
Normalized name: ondansetron 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 16 mg suppository once daily
Study: 8688345
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg tablets twice daily
Study: 6217921
Drug: aspirin/dipyridamole
Normalized name: ASPIRIN/DIPYRIDAMOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin/dipyridamole
Study: 30694697
Drug: Dasotraline 2
Normalized name: Dasotraline
DrugBank: Dasotraline (DB12305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasotraline 2 mg/day
Study: 30007039
Drug: PRF +
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PRF + 1% Alendronate (ALN) gel
Study: 7916914
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate 30 mg
Study: 937355
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate 15 mg
Study: 2811648
Drug: Single drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drug for movement disorder
Study: 2811648
Drug: Potentially useful
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially useful but toxic drug
Study: 20974604
Drug: GW274150 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW274150 60 mg
Study: 22409880
Drug: Prednisolone 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 7.5 mg
Study: 20858230
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of training and RDTs (AB)
Study: 19039291
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (bi-weekly telephone call, no exercise intervention)
Study: 14666757
Drug: TCM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM treatment based on syndrome differentiation of TCM
Study: 14666757
Drug: Conventional method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional method of western medicine (Control)
Study: 11011339
Drug: Unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated Heparin (UFH) - Subtherapeutic
Study: 11011339
Drug: Unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated Heparin (UFH) - Therapeutic
Study: 11011339
Drug: Unfractionated Heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated Heparin (UFH) - Supratherapeutic
Study: 1818759
Drug: Salmon calcitonin
Normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon calcitonin (100 IU) daily injections
Study: 11897434
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum digoxin concentration (0.5 to 0.9 ng/ml)
Study: 11897434
Drug: Moderate serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate serum digoxin concentration (0.9 to 1.2 ng/ml)
Study: 11897434
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum digoxin concentration (>1.2 ng/ml)
Study: 2271507
Drug: Adenine arabinoside
Normalized name: Adenine
DrugBank: Adenine (DB00173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenine arabinoside (Ara‐A) 15 mg/Kg, iv, for 10 days
Study: 31390002
Drug: Nicotinamide riboside
Normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide riboside (NR) at 1000 mg twice daily
Study: 16769988
Drug: EC +
Normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC + G‐CSF
Study: 16769988
Drug: Schedule 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule 5 G‐CSF
Study: 16769988
Drug: Seven or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven or four G‐CSF injections
Study: 11672897
Drug: RIVM hexavalent
Normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIVM hexavalent OMV vaccine (three doses at 0, 2, and 8 months)
Study: 11672897
Drug: RIVM hexavalent
Normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIVM hexavalent OMV vaccine
Study: 12420901
Drug: Problem-solving treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving treatment
Study: 9153693
Drug: Drug placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug placebo with standard clinical management
Study: 2974302
Drug: PTFE (Gore‐Tex
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTFE (Gore‐Tex CV patch)
Study: 21258804
Drug: Mud pack
Normalized name: Cream, Multi Ingredient Topical application Cream [3 ROSES FACIAL MUD PACK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud pack therapy
Study: 21258804
Drug: Hot pack
Normalized name: cold-hot pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hot pack therapy